(Q37791617)

23 August 2017

title

Lenalidomide: a synthetic compound with an evolving role in cancer management (English)

1 reference

23 August 2017

Vassiliki Saloura

1

1 reference

23 August 2017

Petros D. Grivas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20863427

18 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20863427

18 July 2024

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://www.tandfonline.com/doi/pdf/10.1179/102453310X12647083620921

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

18 July 2024

1 reference

23 August 2017

volume

15

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

318-331

1 reference

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Thalidomide: a novel template for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Immunomodulating drugs for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Advances in the therapy of chronic idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Thalidomide and rituximab in Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Phase I study of oral lenalidomide in patients with refractory metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Lenalidomide therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Treatment of plasma cell dyscrasias with lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F102453310X12647083620921

Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis

21 January 2018

7

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Interleukin-6 inhibits apoptosis of malignant plasma cells

18 July 2024

9

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

18 July 2024

17

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

18 July 2024

29

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Antithymocyte globulin for patients with myelodysplastic syndrome

18 July 2024

30

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

18 July 2024

35

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

18 July 2024

41

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy

18 July 2024

42

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

18 July 2024

44

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Phase I study of lenalidomide in solid tumors

18 July 2024

64

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Circadian Infusion of Floxuridine in Patients with Metastatic Renal Cell Carcinoma

18 July 2024

69

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Phase II study of lenalidomide in patients with metastatic renal cell carcinoma

18 July 2024

72

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma

18 July 2024

73

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

Safety and efficacy of lenalidomide (Revlimid) in recurrent ovarian and primary peritoneal carcinoma

18 July 2024

75

1 reference

https://api.crossref.org/works/10.1179/102453310X12647083620921

18 July 2024

Identifiers

1 reference

23 August 2017

1 reference